目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 YEARS CONSIDERED
1.4 INCLUSIONS AND EXCLUSIONS
1.4.1 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 LIMITATIONS
1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Primary sources
2.1.2.2 Key data from primary sources
2.1.2.3 Key industry insights
2.1.2.4 Breakdown of primary interviews
2.2 MARKET SIZE ESTIMATION
2.2.1 APPROACH 1: SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS)
2.2.2 APPROACH 2: COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS
2.2.3 APPROACH 3: BOTTOM-UP APPROACH
2.2.4 APPROACH 4: TOP-DOWN APPROACH
2.2.5 APPROACH 5: DEMAND-SIDE APPROACH
2.2.6 APPROACH 6: VOLUME DATA ANALYSIS
2.2.7 APPROACH 7: ADJACENT MARKET APPROACH
2.2.7.1 Injectable drug delivery market
2.2.7.2 Pharmaceutical drug delivery market
2.3 DATA TRIANGULATION
2.4 MARKET SHARE ESTIMATION
2.5 RESEARCH ASSUMPTIONS
2.5.1 GROWTH RATE ASSUMPTIONS
2.6 RISK ASSESSMENT
2.7 RESEARCH LIMITATIONS
2.7.1 METHODOLOGY-RELATED LIMITATIONS
2.7.2 SCOPE-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 ATTRACTIVE OPPORTUNITIES IN WEARABLE INJECTORS MARKET
4.2 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY APPLICATION AND COUNTRY
4.3 WEARABLE INJECTORS MARKET: REGIONAL MIX
4.4 WEARABLE INJECTORS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.5 WEARABLE INJECTORS MARKET: DEVELOPED VS. DEVELOPING MARKETS

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Rising burden of chronic diseases and aging population
5.2.1.2 Growing preference for home healthcare and self-administration
5.2.1.3 Increased number of R&D activities and strategic partnerships
5.2.1.4 Use of artificial intelligence in diabetes management devices
5.2.2 RESTRAINTS
5.2.2.1 High cost of wearable injectors and lack of reimbursement plans in emerging economies
5.2.2.2 Stringent regulatory requirements for new product approval
5.2.3 OPPORTUNITIES
5.2.3.1 Significant growth potential in emerging economies
5.2.3.2 Integration with digital health & remote monitoring
5.2.4 CHALLENGES
5.2.4.1 Lack of training and education for using wearable injectors
5.3 INDUSTRY TRENDS
5.3.1 INTEGRATION OF SMART CONNECTIVITY & DIGITAL HEALTH FEATURES
5.3.2 LARGE-VOLUME ON-BODY BIOLOGICS INJECTORS
5.4 TECHNOLOGY ANALYSIS
5.4.1 KEY TECHNOLOGIES
5.4.1.1 Micro-MEMS and Bio-MEMS in wearable injectors
5.4.1.2 Electromechanical drive systems (motorized pumps)
5.4.1.3 Sensor-integrated closed-loop wearable injector
5.4.2 COMPLEMENTARY TECHNOLOGIES
5.4.2.1 Smartphone and app interfaces
5.4.2.2 IoT and smart analytics in wearable injectors
5.4.3 ADJACENT TECHNOLOGIES
5.4.3.1 Electrochemical aptamer biosensors
5.4.3.2 Telemedicine platforms
5.5 PORTER'S FIVE FORCES ANALYSIS
5.5.1 THREAT OF NEW ENTRANTS
5.5.2 THREAT OF SUBSTITUTES
5.5.3 BARGAINING POWER OF SUPPLIERS
5.5.4 BARGAINING POWER OF BUYERS
5.5.5 INTENSITY OF COMPETITIVE RIVALRY
5.6 PIPELINE ANALYSIS
5.7 REGULATORY LANDSCAPE
5.7.1 REGULATORY ANALYSIS
5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.8 PATENT ANALYSIS
5.8.1 PATENT PUBLICATION TRENDS FOR WEARABLE INJECTORS
5.8.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
5.9 TRADE ANALYSIS
5.9.1 TRADE DATA FOR HS CODE 901890
5.9.1.1 Import data for HS Code 901890
5.9.1.2 Export data for HS Code 901890
5.10 PRICING ANALYSIS
5.10.1 AVERAGE SELLING PRICE, BY KEY PLAYER
5.10.1.1 Average selling price trend among key players
5.10.2 AVERAGE SELLING PRICE, BY REGION
5.10.2.1 Average selling price trend of on-body wearable injector, by region
5.10.2.2 Average selling price trend of off-body wearable injector, by region
5.11 REIMBURSEMENT ANALYSIS
5.12 KEY CONFERENCES & EVENTS, 2025-2026
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS (DEVICES)
5.13.2 KEY STAKEHOLDERS IN BUYING PROCESS (FORMULATIONS)
5.13.3 BUYING CRITERIA
5.14 UNMET NEEDS/END-USER EXPECTATIONS
5.15 IMPACT OF AI ON WEARABLE INJECTORS MARKET
5.15.1 INTRODUCTION
5.15.2 MARKET POTENTIAL IN WEARABLE INJECTORS ECOSYSTEM
5.15.3 AI USE CASES
5.15.4 KEY COMPANIES IMPLEMENTING AI IN WEARABLE INJECTORS
5.15.5 FUTURE OF GEN AI IN WEARABLE INJECTORS ECOSYSTEM
5.16 ECOSYSTEM ANALYSIS
5.16.1 WEARABLE INJECTOR PROVIDERS
5.16.2 END USERS
5.16.3 REGULATORY BODIES
5.17 VALUE CHAIN ANALYSIS
5.18 INVESTMENT AND FUNDING SCENARIO
5.19 IMPACT OF 2025 US TARIFF
5.19.1 INTRODUCTION
5.19.2 KEY TARIFF RATES
5.19.3 PRICE IMPACT ANALYSIS
5.19.4 IMPACT ON COUNTRY/REGION
5.19.5 IMPACT ON END-USE INDUSTRIES
5.20 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS

6 WEARABLE INJECTORS MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 ON-BODY WEARABLE INJECTORS
6.2.1 LARGE-VOLUME SUBCUTANEOUS DELIVERY AND HOME-BASED CARE TO DRIVE MARKET
6.3 OFF-BODY WEARABLE INJECTORS
6.3.1 TECHNOLOGICAL VERSATILITY AND PERSONALIZED DRUG DELIVERY TO DRIVE MARKET

7 WEARABLE INJECTORS MARKET, BY DELIVERY METHOD
7.1 INTRODUCTION
7.2 PROGRAMMED/CONTINUOUS INFUSION
7.2.1 NEED FOR PRECISE, CONTROLLED DRUG DELIVERY OVER EXTENDED DURATIONS TO DRIVE SEGMENT
7.3 BOLUS-ONLY
7.3.1 GROWING DEMAND FOR SELF-ADMINISTERED, SINGLE-DOSE BIOLOGICS TO DRIVE SEGMENT GROWTH

8 WEARABLE INJECTORS MARKET, BY END USER
8.1 INTRODUCTION
8.2 WEARABLE INJECTOR FORMULATION END USERS
8.2.1 HOME CARE SETTINGS
8.2.1.1 RISING PREFERENCE FOR SELF-ADMINISTRATION OF MEDICINE TO DRIVE MARKET
8.2.2 HOSPITALS & CLINICS
8.2.2.1 Increased hospital demand for controlled drug delivery boosting market uptake
8.2.3 SPECIALTY INFUSION CENTERS/AMBULATORY SURGERY CENTERS
8.2.3.1 Cost-efficiency to drive demand for wearable injectors in specialty centers
8.2.4 OTHER FORMULATION END USERS
8.3 WEARABLE INJECTOR DEVICE END USERS
8.3.1 PHARMACEUTICAL COMPANIES
8.3.1.1 Need for efficient subcutaneous delivery of large-volume biologics to drive market
8.3.2 BIOTECHNOLOGY COMPANIES
8.3.2.1 Improved patient experience, dose accuracy, and at-home administration of complex biologics to drive market
8.3.3 CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS
8.3.3.1 Innovation through cost-effective and scalable manufacturing solutions to drive market

9 WEARABLE INJECTORS MARKET, BY TECHNOLOGY
9.1 INTRODUCTION
9.2 SPRING-BASED TECHNOLOGY
9.2.1 COST-EFFECTIVE ENGINEERING AND MECHANICAL SIMPLICITY TO DRIVE MARKET
9.3 MOTOR-DRIVEN TECHNOLOGY
9.3.1 PRECISION DOSING AND PROGRAMMABILITY ACCELERATING ADOPTION OF MOTOR-BASED WEARABLE INJECTORS
9.4 ROTARY PUMP TECHNOLOGY
9.4.1 HIGHER PRECISION AND BETTER CONTROL OVER VISCOUS MEDICINES TO SUPPORT MARKET GROWTH
9.5 EXPANDING BATTERY TECHNOLOGY
9.5.1 SHIFT TOWARD HIGH-VOLUME DELIVERY OF VISCOUS DRUGS TO BOOST DEMAND
9.6 OTHER TECHNOLOGIES

10 WEARABLE INJECTORS MARKET, BY THERAPEUTIC APPLICATION
10.1 INTRODUCTION
10.2 AUTOIMMUNE DISEASES
10.2.1 GROWING PREFERENCE FOR SELF-ADMINISTRATION IN CHRONIC AUTOIMMUNE DISORDERS TO FUEL DEMAND
10.3 DIABETES
10.3.1 HIGH DISEASE BURDEN AND DAILY INJECTION DEMAND FUEL MARKET DOMINANCE
10.4 ONCOLOGY
10.4.1 INCREASING NUMBER OF CANCER CASES, SHIFT TOWARD SUBCUTANEOUS CANCER THERAPIES, AND NEED TO REDUCE HOSPITAL BURDEN TO BOOST MARKET
10.5 CARDIOVASCULAR DISEASES
10.5.1 RISING NEED FOR CONTINUOUS DRUG DELIVERY IN PULMONARY AND CARDIORENAL CONDITIONS TO DRIVE DEMAND
10.6 INFECTIOUS DISEASES
10.6.1 NEED FOR RAPID AND SELF-ADMINISTERED TREATMENT TO DRIVE ADOPTION
10.7 RARE/ORPHAN DISEASES
10.7.1 HIGH-COST BIOLOGICS AND PERSONALIZED TREATMENT NEEDS TO DRIVE DEMAND
10.8 OTHER THERAPEUTIC APPLICATIONS

11 WEARABLE INJECTORS MARKET, BY USAGE
11.1 INTRODUCTION
11.2 DISPOSABLE
11.2.1 RISING PREFERENCE FOR SIMPLICITY, STERILITY, AND SINGLE-USE SAFETY TO DRIVE DISPOSABLE WEARABLE INJECTORS MARKET
11.3 REUSABLE
11.3.1 ENABLING LONG-TERM COST EFFICIENCY AND SUSTAINABLE DRUG DELIVERY MODELS TO DRIVE DEMAND

12 WEARABLE INJECTORS MARKET, BY REGION
12.1 INTRODUCTION
12.2 NORTH AMERICA
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
12.2.2 US
12.2.2.1 Growing home healthcare market to drive demand
12.2.3 CANADA
12.2.3.1 Rising biologic usage and decentralized care pathways to boost demand
12.3 EUROPE
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
12.3.2 GERMANY
12.3.2.1 Domestic medtech innovation and government initiatives to fuel growth
12.3.3 UK
12.3.3.1 NHS digital strategy and homecare shift to accelerate wearable injector adoption
12.3.4 FRANCE
12.3.4.1 Well-established healthcare system to support market growth
12.3.5 ITALY
12.3.5.1 Growing demand for cost-effective home care to drive market
12.3.6 SPAIN
12.3.6.1 Rising prevalence of cancer to drive demand
12.3.7 NETHERLANDS
12.3.7.1 Strong healthcare infrastructure and aging population to drive market growth
12.3.8 REST OF EUROPE
12.4 ASIA PACIFIC
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
12.4.2 CHINA
12.4.2.1 Growing investments in healthcare infrastructure to drive market
12.4.3 JAPAN
12.4.3.1 Large geriatric population to drive demand
12.4.4 INDIA
12.4.4.1 Increasing demand for advanced medical treatment to boost market
12.4.5 AUSTRALIA
12.4.5.1 Rising prevalence of chronic diseases to fuel market
12.4.6 THAILAND
12.4.6.1 Expansion of universal healthcare to drive growth of wearable injectors market
12.4.7 VIETNAM
12.4.7.1 Rapidly aging population to drive demand
12.4.8 SOUTH KOREA
12.4.8.1 Rise of geriatric population to drive growth
12.4.9 INDONESIA
12.4.9.1 Growing emphasis on home-based care and universal coverage to drive adoption of wearable injectors
12.4.10 REST OF ASIA PACIFIC
12.5 LATIN AMERICA
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
12.5.2 BRAZIL
12.5.2.1 Increasing number of chronic conditions to drive market
12.5.3 MEXICO
12.5.3.1 Government initiatives to boost wearable injectors market
12.5.4 REST OF LATIN AMERICA
12.6 MIDDLE EAST & AFRICA
12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
12.6.2 GCC COUNTRIES
12.6.2.1 Kingdom of Saudi Arabia (KSA)
12.6.2.1.1 Smart healthcare infrastructure and chronic disease burden to propel market expansion
12.6.2.2 United Arab Emirates (UAE)
12.6.2.2.1 Government support and digital health initiatives to fuel UAE's wearable injectors market
12.6.2.3 Rest of GCC Countries
12.6.3 REST OF MIDDLE EAST & AFRICA

13 COMPETITIVE LANDSCAPE
13.1 OVERVIEW
13.2 KEY PLAYER STRATEGY/RIGHT TO WIN
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN WEARABLE INJECTORS MARKET
13.3 REVENUE ANALYSIS, 2020-2024
13.3.1 WEARABLE INJECTOR DEVICE MANUFACTURERS
13.3.2 WEARABLE INJECTOR FORMULATION MANUFACTURERS
13.4 MARKET SHARE ANALYSIS
13.4.1 WEARABLE INJECTOR DEVICE MANUFACTURERS
13.4.2 GLOBAL MARKET SHARE ANALYSIS OF WEARABLE DEVICE MANUFACTURERS, 2024
13.4.3 US MARKET SHARE ANALYSIS OF WEARABLE DEVICE MANUFACTURERS, 2024
13.4.4 WEARABLE INJECTOR FORMULATION MANUFACTURERS
13.4.5 GLOBAL MARKET SHARE ANALYSIS OF WEARABLE FORMULATION MANUFACTURERS, 2024
13.4.6 US MARKET SHARE ANALYSIS OF WEARABLE FORMULATION MANUFACTURERS, 2024
13.5 COMPANY EVALUATION MATRIX: DEVICE KEY PLAYERS, 2024
13.5.1 STARS
13.5.2 EMERGING LEADERS
13.5.3 PERVASIVE PLAYERS
13.5.4 PARTICIPANTS
13.5.5 COMPANY FOOTPRINT: DEVICE KEY PLAYERS, 2024
13.5.5.1 Company footprint
13.5.5.2 Region footprint
13.5.5.3 Product type footprint
13.5.5.4 Usage footprint
13.5.5.5 Delivery method footprint
13.5.5.6 Technology type footprint
13.6 COMPANY EVALUATION MATRIX: DEVICE STARTUPS/SMES, 2024
13.6.1 PROGRESSIVE COMPANIES
13.6.2 DYNAMIC COMPANIES
13.6.3 STARTING BLOCKS
13.6.4 RESPONSIVE COMPANIES
13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
13.6.5.1 Detailed list of key device startups/SME players
13.6.5.2 Competitive benchmarking of key SMEs/startups
13.7 COMPANY EVALUATION MATRIX: FORMULATION KEY PLAYERS, 2024
13.7.1 STARS
13.7.2 EMERGING LEADERS
13.7.3 PERVASIVE PLAYERS
13.7.4 PARTICIPANTS
13.7.5 COMPANY FOOTPRINT: FORMULATION KEY PLAYERS, 2024
13.7.5.1 Company footprint
13.7.5.2 Region footprint
13.7.5.3 Product type footprint
13.7.5.4 Delivery method footprint
13.7.5.5 Therapeutic application footprint
13.7.5.6 Technology type footprint
13.8 BRAND/PRODUCT COMPARISON
13.9 R&D EXPENDITURE OF KEY PLAYERS
13.10 COMPANY VALUATION AND FINANCIAL METRICS
13.10.1 COMPANY VALUATION
13.10.2 FINANCIAL METRICS
13.11 COMPETITIVE SCENARIO
13.11.1 PRODUCT LAUNCHES & APPROVALS
13.11.2 DEALS
13.11.3 EXPANSIONS
13.11.4 OTHER DEVELOPMENTS

14 COMPANY PROFILES
14.1 WEARABLE INJECTORS DEVICE MANUFACTURERS
14.2 KEY PLAYERS
14.2.1 INSULET CORPORATION
14.2.1.1 Business overview
14.2.1.2 Products/Solutions/Services offered
14.2.1.3 Recent developments
14.2.1.3.1 Product launches, upgrades, and approvals
14.2.1.3.2 Deals
14.2.1.3.3 Expansions
14.2.1.4 MnM view
14.2.1.4.1 Key strengths
14.2.1.4.2 Strategic choices
14.2.1.4.3 Weaknesses & competitive threats
14.2.2 TANDEM DIABETES CARE, INC.
14.2.2.1 Business overview
14.2.2.2 Products/Solutions/Services offered
14.2.2.3 Recent developments
14.2.2.3.1 Product launches, upgrades, and approvals
14.2.2.3.2 Deals
14.2.2.4 MnM view
14.2.2.4.1 Key strengths
14.2.2.4.2 Strategic choices
14.2.2.4.3 Weaknesses & competitive threats
14.2.3 MEDTRONIC
14.2.3.1 Business overview
14.2.3.2 Products/Solutions/Services offered
14.2.3.3 Recent developments
14.2.3.3.1 Product launches, upgrades, and approvals
14.2.3.3.2 Deals
14.2.3.4 MnM view
14.2.3.4.1 Key strengths
14.2.3.4.2 Strategic choices
14.2.3.4.3 Weaknesses & competitive threats
14.2.4 BD
14.2.4.1 Business overview
14.2.4.2 Products/Solutions/Services offered
14.2.4.3 Recent developments
14.2.4.3.1 Deals
14.2.4.3.2 Expansions
14.2.4.3.3 Other developments
14.2.4.4 MnM view
14.2.4.4.1 Key strengths
14.2.4.4.2 Strategic choices
14.2.4.4.3 Weaknesses & competitive threats
14.2.5 WEST PHARMACEUTICAL SERVICES, INC.
14.2.5.1 Business overview
14.2.5.2 Products/Solutions/Services offered
14.2.5.3 Recent developments
14.2.5.3.1 Expansions
14.2.5.4 MnM view
14.2.5.4.1 Key strengths
14.2.5.4.2 Strategic choices
14.2.5.4.3 Weaknesses & competitive threats
14.2.6 GERRESHEIMER AG
14.2.6.1 Business overview
14.2.6.2 Products/Solutions/Services offered
14.2.6.3 Recent developments
14.2.6.3.1 Expansions
14.2.7 STEVANATO
14.2.7.1 Business overview
14.2.7.2 Products/Solutions/Services offered
14.2.7.3 Recent developments
14.2.7.3.1 Product launches, upgrades, and approvals
14.2.7.3.2 Deals
14.2.8 LTS LOHMANN THERAPIE-SYSTEME AG
14.2.8.1 Business overview
14.2.8.2 Products/Solutions/Services offered
14.2.8.3 Recent developments
14.2.8.3.1 Product launches, upgrades, and approvals
14.2.8.3.2 Deals
14.2.8.3.3 Expansions
14.2.9 SONCEBOZ
14.2.9.1 Business overview
14.2.9.2 Products/Solutions/Services offered
14.2.10 NEMERA
14.2.10.1 Business overview
14.2.10.2 Products/Solutions/Services offered
14.2.10.3 Recent developments
14.2.10.3.1 Deals
14.2.10.3.2 Expansions
14.2.11 MANNKIND CORPORATION
14.2.11.1 Business overview
14.2.11.2 Products/Solutions/Services offered
14.2.11.3 Recent developments
14.2.11.3.1 Deals
14.2.12 ENABLE INJECTIONS, INC.
14.2.12.1 Business overview
14.2.12.2 Products/Solutions/Services offered
14.2.12.3 Recent developments
14.2.12.3.1 Product launches, upgrades, and approvals
14.2.12.3.2 Deals
14.2.12.3.3 Expansions
14.2.12.3.4 Other developments
14.2.13 ELCAM MEDICAL
14.2.13.1 Business overview
14.2.13.2 Products/Solutions/Services offered
14.2.13.3 Recent developments
14.2.13.3.1 Expansions
14.3 OTHER PLAYERS
14.3.1 DEBIOTECH SA
14.3.2 MEDTRUM TECHNOLOGIES INC.
14.3.3 CEQUR SIMPLICITY
14.3.4 SUBCUJECT APS
14.3.5 MICROMED CO., LTD
14.4 WEARABLE INJECTORS WITH FORMULATION MANUFACTURERS
14.4.1 AMGEN INC.
14.4.1.1 Business overview
14.4.1.2 Products/Solutions/Services offered
14.4.1.3 Recent developments
14.4.1.3.1 Deals
14.4.1.3.2 Expansions
14.4.2 ABBVIE INC.
14.4.2.1 Business overview
14.4.2.2 Products/Solutions/Services offered
14.4.2.3 Recent developments
14.4.2.3.1 Product launches, upgrades, and approvals
14.4.2.3.2 Expansions
14.4.3 UNITED THERAPEUTICS CORPORATION
14.4.3.1 Business overview
14.4.3.2 Products/Solutions/Services offered
14.4.3.3 Recent developments
14.4.3.3.1 Expansions
14.4.4 APELLIS PHARMACEUTICALS, INC.
14.4.4.1 Business overview
14.4.4.2 Products/Solutions/Services offered
14.4.4.3 Recent developments
14.4.4.3.1 Product launches, upgrades, and approvals
14.4.5 SUPERNUS PHARMACEUTICALS
14.4.5.1 Business overview
14.4.5.2 Products/Solutions/Services offered
14.4.5.3 Recent developments
14.4.5.3.1 Product launches, upgrades, and approvals
14.4.6 COHERUS BIOSCIENCES, INC.
14.4.6.1 Business overview
14.4.6.2 Products/Solutions/Services offered
14.4.6.3 Recent developments
14.4.6.3.1 Product launches, upgrades, and approvals
14.4.6.3.2 Other developments
14.4.7 SCPHARMACEUTICALS, INC.
14.4.7.1 Business overview
14.4.7.2 Products/Solutions/Services offered
14.4.7.3 Recent developments
14.4.7.3.1 Product launches, upgrades and approvals

15 APPENDIX
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS